Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing
This article was originally published in The Pink Sheet Daily
Executive Summary
A six-year-old start-up founded by Vicuron veterans has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.